Redwire BioFabrication Facility Successfully Prints First Human Knee Meniscus on ISS, Paving the Way for Advanced In-Space Bioprinting Capabilities to Benefit Human Health
07 September 2023 - 1:30PM
Business Wire
Redwire Corporation (NYSE: RDW), a leader in space
infrastructure for the next generation space economy, announced
today that it has successfully 3D bioprinted the first human knee
meniscus on orbit using its upgraded 3D BioFabrication Facility
(BFF) on the International Space Station (ISS). This milestone
opens the door to improved treatments for meniscal injuries, one of
the most common injuries for U.S. Service Members.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20230907832309/en/
Redwire’s 3D BioFabrication Facility
successfully 3D printed the first human knee meniscus on the
International Space Station, paving the way for advanced in-space
bioprinting capabilities to benefit human health. (Credit:
Redwire)
“This is a groundbreaking milestone with significant
implications for human health,” said Redwire Executive Vice
President John Vellinger. “Demonstrating the ability to
successfully print complex tissue such as this meniscus is a major
leap forward toward the development of a repeatable microgravity
manufacturing process for reliable bioprinting at scale.”
The print returned to Earth onboard the SpaceX Crew-6 Mission
for analysis following successful print operations in July. Before
returning to Earth, the print was cultured for 14 days on the ISS
in Redwire’s Advanced Space Experiment Processor (ADSEP). The print
was conducted as part of the BFF-Meniscus-2 Investigation with the
Uniformed Services University of the Health Sciences Center for
Biotechnology (4D Bio3), a biomedical research center that explores
and adapts promising biotechnologies for warfighter benefit. The
investigation was conducted by NASA astronauts Frank Rubio, Warren
“Woody” Hoburg, and Stephen Bowen, and UAE astronaut Sultan Al
Neyadi.
BFF is part of Redwire’s growing portfolio of technologies and
innovative on-orbit capabilities enabling human spaceflight
missions and commercial microgravity research and development in
low-Earth orbit (LEO). Redwire has developed 20 research facilities
for the ISS with 10 currently operating on station to deliver
world-leading research. In July, Redwire announced plans to open a
30,000 square foot, state-of-the-art microgravity payload
development facility with a mission operations center at the
Novaparke Innovation & Technology Campus in Floyd County,
Indiana, as the company looks to increase production of critical
technologies enabling human spaceflight missions and commercial
microgravity research and development in LEO.
On the upcoming SpaceX CRS-29 resupply mission to the ISS in
November, Redwire will be launching microgravity research payloads
focused on pharmaceutical drug development and regenerative
medicine, including an experiment in bioprinting cardiac
tissue.
About Redwire
Redwire Corporation (NYSE: RDW) is a global leader in mission
critical space solutions and high reliability components for the
next generation space economy, with valuable intellectual property
for solar power generation, in-space 3D printing and manufacturing,
avionics, critical components, sensors, digital engineering and
space-based biotechnology. It combines decades of flight heritage
with an agile and innovative culture. The company’s “Heritage plus
Innovation” strategy enables it to combine proven performance with
new, innovative capabilities to provide its customers with the
building blocks for the present and future of space infrastructure.
For more information, please visit redwirespace.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230907832309/en/
Media Contact: Emily Devine Emily.Devine@redwirespace.com
305-632-9137
OR
Investors: investorrelations@redwirespace.com
904-425-1431
Redwire (NYSE:RDW)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
Redwire (NYSE:RDW)
Historical Stock Chart
Von Mai 2023 bis Mai 2024